ArticleDiscover oncology2026
Chemotherapy as a protective factor against cardiocerebrovascular disease mortality in colorectal cancer patients based on SEER database.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe impact of chemotherapy on cardiocerebrovascular disease (CCVD) outcomes in patients with colorectal cancer (CRC) remains insufficiently explored. This research aimed to clarify the association between chemotherapy and CCVD-related mortality in middle-aged and elderly CRC patients.
methodsCRC patients aged ≥ 50 years at diagnosis were identified from the Surveillance, Epidemiology, and End Results (SEER) database for the period 2010–2015. The primary outcome was CCVD-related mortality. Survival analyses included Kaplan-Meier (KM) curves to characterize CCVD-related survival patterns and multivariate competing risks regression analysis to evaluate the independent association between chemotherapy and CCVD-related mortality. Subgroup analyses and Fine-Gray competing risks models were additionally performed to enhance the robustness of study findings.
resultsA total of 136 095 CRC patients were included. KM analysis showed a significantly lower cumulative risk of CCVD-related mortality in chemotherapy treatment group than in non-chemotherapy treatment group. After adjusting for age, race, gender, primary tumor site, and tumor stage, multivariate competing risks regression analysis confirmed that chemotherapy was an independent protective factor against CCVD-related mortality (sHR = 0.75, 95% CI 0.71–0.79, P < 0.001). Subgroup analyses and Fine-Gray competing risks models further validated the robustness of chemotherapy’s beneficial effect on CCVD outcomes.
conclusionChemotherapy may serve as an independent protective factor against CCVD-related mortality in CRC patients. These findings can help alleviate concerns regarding chemotherapy-associated CCVD risk in CRC management and provide novel insights for clinical decision-making and future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.